that’s very interesting.
given that they’re projecting needing to do the trial on n=250 patients. I wonder if they’re covering that number between sites in the UK and the US, or whether they have to double that number to satisfy the FDA.
given that the EMA only wants one trial, I would imagine invex would only run the ICP outcome in Europe only.
- Forums
- ASX - By Stock
- IXC
- Ann: Invex Granted Type C Meeting with FDA
Ann: Invex Granted Type C Meeting with FDA, page-100
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
6.3¢ |
Change
-0.007(10.0%) |
Mkt cap ! $5.260M |
Open | High | Low | Value | Volume |
7.0¢ | 7.0¢ | 6.3¢ | $4.485K | 65.57K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.5¢ | 8695 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.070 |
1 | 84879 | 0.063 |
1 | 100000 | 0.062 |
2 | 158500 | 0.060 |
1 | 100000 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.075 | 8695 | 1 |
0.079 | 30837 | 1 |
0.080 | 19000 | 2 |
0.083 | 4000 | 1 |
0.090 | 126146 | 1 |
Last trade - 11.20am 20/08/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |